T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.
|Poll|April 30, 2015
A Breast Biopsy is Performed on a 45-Year-Old Woman With Microcalcifications
Author(s)Cesar A. Moran, MD
A breast biopsy is performed on a 45-year-old woman with microcalcifications detected from a mammogram. What is your diagnosis?
Advertisement
A breast biopsy is performed on a 45-year-old woman with microcalcifications detected from a mammogram. According to the histopathology image below, what is your diagnosis?
What is your diagnosis?
Advertisement
Related to this article
Data from the phase 3 EMBER-3 trial support the full approval of imlunestrant plus abemaciclib in this breast cancer population.
NICE recommended trastuzumab deruxtecan for reimbursement in England for HER2-low metastatic breast cancer, backed by DESTINY-Breast04 data.
Trastuzumab botidotin more than doubled median PFS vs trastuzumab emtansine in HER2-positive advanced breast cancer in the phase 3 KL166-III-06 trial.
Camizestrant/palbociclib did not significantly improve PFS vs anastrozole/palbociclib in first-line ER+/HER2– breast cancer in the phase 3 SERENA-4 trial.
Erica L. Mayer, MD, MPH, discussed the practical questions clinicians must answer as the SERENA-6 early-switch approach with camizestrant enters practice.
Erica L. Mayer, MD, MPH, explained why oncologists should switch to camizestrant at ESR1 mutation emergence rather than reserve oral SERDs for progression.